BUSINESS WIRE: QIAGEN announces worldwide shipments of QIAstat-Dx test kits for SARS-CoV-2

26.02.2020, 22:00 Uhr

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

  • QIAstat-Dx Respiratory 2019-nCoV Panel rapidly differentiates novel coronavirus from 21 other pathogens implicated in serious respiratory syndromes
  • Panel being tested at four hospitals in China after initial evaluation on clinical samples by a leading Paris hospital
  • Adds to QIAGEN's portfolio of molecular testing solutions to aid in global public health emergency

HILDEN, Germany & GERMANTOWN, Maryland --(BUSINESS WIRE)-- 26.02.2020 --

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has shipped its newly developed QIAstat-Dx Respiratory Panel 2019-nCoV test kit to four hospitals in China for evaluation. The new kit detects the novel coronavirus SARS-CoV-2 and adds rapid Sample to Insight syndromic testing to QIAGEN's portfolio of molecular testing solutions in the public health emergency. QIAGEN is also in the process of shipping QIAstat-Dx testing kits to public health institutions in other regions, including Europe, South-East Asia, and the Middle East.

Since January QIAGEN has been providing instruments and consumables to support detection of the virus in China and other markets. Official protocols for SARS-CoV-2 detection include QIAGEN extraction kits, reagents and instruments for real-time polymerase chain reaction (RT-PCR) workflows. Customers also are deploying QIAsymphony modular instruments and NeuMoDx integrated PCR systems to automate higher-throughput processing of their laboratory-developed tests for SARS-CoV-2.

"Our dedicated task force has moved very fast to develop and make available the QIAstat-Dx respiratory panel with SARS-CoV-2 detection. We are partnering closely with authorities and customers around the world to bring rapid, accurate diagnosis to the fight against this deadly infectious disease," said Thierry Bernard, Interim CEO of QIAGEN and Senior Vice President, Head of the Molecular Diagnostics Business Area. "As we have in past health crises such as SARS and the swine flu, QIAGEN is working hard to deliver better, faster testing solutions for hospitals and public health institutions to aid in the effort to monitor and bring the outbreak under control. Our employees' extraordinary response embodies QIAGEN's core mission to make improvements in life possible."

Please find the full press release here

Anzeige

Further information can be also found here

QIAGEN
Investor Relations
John Gilardi

+49 2103 29 11711

Phoebe Loh
+49 2103 29 11457
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer
+49 2103 29 11826

Robert Reitze
+49 2103 29 11676
e-mail: pr@QIAGEN.com

Weitere Nachrichten

02.04. BUSINESS WIRE: Yokogawa erhält Lieferauftrag für ein Gaskraftwerk in Turkmenistan
02.04. BUSINESS WIRE:  Mehr Power für alle: professionell arbeiten, professionell spielen GIGABYTE AERO/AORUS definiert Notebooks für Profis neu
02.04. BUSINESS WIRE: REPLY: Reply Code Challenge verzeichnet über 20.000 Teilnehmer aus 96 Ländern weltweit
02.04. BUSINESS WIRE: Esri versorgt WHO-Mitgliedsstaaten mit Mapping-Ressourcen
02.04. BUSINESS WIRE: Stone Estate.Swiss Management AG beruft Alastair Manning zum Managing Director und Head of Asset Management
02.04. BUSINESS WIRE: Der europäische Webhoster IKOULA unterstützt mit seinen kooperativen Arbeits-, Backup- und Storage-Lösungen alle Unternehmen bei der Aufrechterhaltung ihres Geschäftsbetriebs während der Corona-Krise.
02.04. BUSINESS WIRE: RELIEF THERAPEUTICS Holding SA Announces the Closing of its Share Exchange Agreement with Sonnet BioTherapeutics, Inc. for the Divestment of its wholly-owned Subsidiary Relief Therapeutics SA
02.04. BUSINESS WIRE: Startup-Unternehmen für künstliche Intelligenz startet weltweiten Service für automatisiertes Branding
02.04. BUSINESS WIRE: NOXXON GIBT DEN ABSCHLUSS DER PATIENTENREKRUTIERUNG FÜR DIE ERSTE DOSISGRUPPE IN DER PHASE 1/2-KOMBINATIONSSTUDIE MIT NOX-A12 UND STRAHLENTHERAPIE ZUR BEHANDLUNG VON GEHIRNTUMOREN BEKANNT
02.04. BUSINESS WIRE: Athora Completes Acquisition of VIVAT and Provides a Capital Injection of €400 Million
Anzeige
Anzeige